Skip to content
TrialScanner

NCT01265901

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Phase 3CompletedIMTXLead

Registry record

Lead sponsor
Immatics Biotechnologies GmbH
Conditions
Metastatic Renal Cell Carcinoma
Primary completion
Jul 2015Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01265901 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01265901: IMA901 in Patients Receiving... | TrialScanner